129 related articles for article (PubMed ID: 35343875)
1. An optimized agonist peptide of protease-activated receptor 4 and its use in a validated platelet-aggregation assay.
Yang J; Mapelli C; Wang Z; Sum CS; Hua J; Lawrence RM; Ni Y; Seiffert DA
Platelets; 2022 Oct; 33(7):979-986. PubMed ID: 35343875
[TBL] [Abstract][Full Text] [Related]
2. The protease-activated receptor 4 Ala120Thr variant alters platelet responsiveness to low-dose thrombin and protease-activated receptor 4 desensitization, and is blocked by non-competitive P2Y
Whitley MJ; Henke DM; Ghazi A; Nieman M; Stoller M; Simon LM; Chen E; Vesci J; Holinstat M; McKenzie SE; Shaw CA; Edelstein LC; Bray PF
J Thromb Haemost; 2018 Dec; 16(12):2501-2514. PubMed ID: 30347494
[TBL] [Abstract][Full Text] [Related]
3. Structure-function analysis of protease-activated receptor 4 tethered ligand peptides. Determinants of specificity and utility in assays of receptor function.
Faruqi TR; Weiss EJ; Shapiro MJ; Huang W; Coughlin SR
J Biol Chem; 2000 Jun; 275(26):19728-34. PubMed ID: 10779527
[TBL] [Abstract][Full Text] [Related]
4. The ATP-gated P2X1 receptor plays a pivotal role in activation of aspirin-treated platelets by thrombin and epinephrine.
Grenegård M; Vretenbrant-Oberg K; Nylander M; Désilets S; Lindström EG; Larsson A; Ramström I; Ramström S; Lindahl TL
J Biol Chem; 2008 Jul; 283(27):18493-504. PubMed ID: 18480058
[TBL] [Abstract][Full Text] [Related]
5. Molecular basis for activation and biased signaling at the thrombin-activated GPCR proteinase activated receptor-4 (PAR4).
Thibeault PE; LeSarge JC; Arends D; Fernandes M; Chidiac P; Stathopulos PB; Luyt LG; Ramachandran R
J Biol Chem; 2020 Feb; 295(8):2520-2540. PubMed ID: 31892516
[TBL] [Abstract][Full Text] [Related]
6. Protease-activated receptors 1 and 4 do not stimulate G(i) signaling pathways in the absence of secreted ADP and cause human platelet aggregation independently of G(i) signaling.
Kim S; Foster C; Lecchi A; Quinton TM; Prosser DM; Jin J; Cattaneo M; Kunapuli SP
Blood; 2002 May; 99(10):3629-36. PubMed ID: 11986217
[TBL] [Abstract][Full Text] [Related]
7. First-in-human study to assess the safety, pharmacokinetics, and pharmacodynamics of BMS-986141, a novel, reversible, small-molecule, PAR4 agonist in non-Japanese and Japanese healthy participants.
Merali S; Wang Z; Frost C; Meadows-Shropshire S; Hawthorne D; Yang J; Seiffert D
Platelets; 2023 Dec; 34(1):2222846. PubMed ID: 37394920
[TBL] [Abstract][Full Text] [Related]
8. Platelet protease-activated receptor (PAR)4, but not PAR1, associated with neutral sphingomyelinase responsible for thrombin-stimulated ceramide-NF-κB signaling in human platelets.
Chen WF; Lee JJ; Chang CC; Lin KH; Wang SH; Sheu JR
Haematologica; 2013 May; 98(5):793-801. PubMed ID: 23065519
[TBL] [Abstract][Full Text] [Related]
9. Blocking the protease-activated receptor 1-4 heterodimer in platelet-mediated thrombosis.
Leger AJ; Jacques SL; Badar J; Kaneider NC; Derian CK; Andrade-Gordon P; Covic L; Kuliopulos A
Circulation; 2006 Mar; 113(9):1244-54. PubMed ID: 16505172
[TBL] [Abstract][Full Text] [Related]
10. Protease-Activated Receptor 4 Variant p.Tyr157Cys Reduces Platelet Functional Responses and Alters Receptor Trafficking.
Norman JE; Cunningham MR; Jones ML; Walker ME; Westbury SK; Sessions RB; Mundell SJ; Mumford AD
Arterioscler Thromb Vasc Biol; 2016 May; 36(5):952-60. PubMed ID: 26966273
[TBL] [Abstract][Full Text] [Related]
11. PAR4 (Protease-Activated Receptor 4) Antagonism With BMS-986120 Inhibits Human Ex Vivo Thrombus Formation.
Wilson SJ; Ismat FA; Wang Z; Cerra M; Narayan H; Raftis J; Gray TJ; Connell S; Garonzik S; Ma X; Yang J; Newby DE
Arterioscler Thromb Vasc Biol; 2018 Feb; 38(2):448-456. PubMed ID: 29269513
[TBL] [Abstract][Full Text] [Related]
12. Discovery of Potent and Selective Quinoxaline-Based Protease-Activated Receptor 4 (PAR4) Antagonists for the Prevention of Arterial Thrombosis.
Zhang X; Jiang W; Richter JM; Bates JA; Reznik SK; Stachura S; Rampulla R; Doddalingappa D; Ulaganathan S; Hua J; Bostwick JS; Sum C; Posy S; Malmstrom S; Dickey J; Harden D; Lawrence RM; Guarino VR; Schumacher WA; Wong P; Yang J; Gordon DA; Wexler RR; Priestley ES
J Med Chem; 2024 Mar; 67(5):3571-3589. PubMed ID: 38385264
[TBL] [Abstract][Full Text] [Related]
13. Blockade of protease-activated receptor-4 (PAR4) provides robust antithrombotic activity with low bleeding.
Wong PC; Seiffert D; Bird JE; Watson CA; Bostwick JS; Giancarli M; Allegretto N; Hua J; Harden D; Guay J; Callejo M; Miller MM; Lawrence RM; Banville J; Guy J; Maxwell BD; Priestley ES; Marinier A; Wexler RR; Bouvier M; Gordon DA; Schumacher WA; Yang J
Sci Transl Med; 2017 Jan; 9(371):. PubMed ID: 28053157
[TBL] [Abstract][Full Text] [Related]
14. Protease-activated receptor-4 (PAR4) variant influences on platelet reactivity induced by PAR4-activating peptide through altered Ca
Morikawa Y; Kato H; Kashiwagi H; Nishiura N; Akuta K; Honda S; Kanakura Y; Tomiyama Y
Thromb Res; 2018 Feb; 162():44-52. PubMed ID: 29289806
[TBL] [Abstract][Full Text] [Related]
15. Protease-activated receptor (PAR) 1 and PAR4 differentially regulate factor V expression from human platelets.
Duvernay M; Young S; Gailani D; Schoenecker J; Hamm HE
Mol Pharmacol; 2013 Apr; 83(4):781-92. PubMed ID: 23307185
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and evaluation of novel and potent protease activated receptor 4 (PAR4) antagonists based on a quinazolin-4(3H)-one scaffold.
Liu S; Yuan D; Li S; Xie R; Kong Y; Zhu X
Eur J Med Chem; 2021 Dec; 225():113764. PubMed ID: 34391031
[TBL] [Abstract][Full Text] [Related]
17. [Role of adenosine diphosphate in the course of thrombin signal transmission].
Han Y; Lu XX; Wang ZY; Dai L; Shen WH; Wu DP; Ruan CG
Zhonghua Yi Xue Za Zhi; 2006 Dec; 86(46):3299-301. PubMed ID: 17313817
[TBL] [Abstract][Full Text] [Related]
18. Regulation of protease-activated receptor (PAR) 1 and PAR4 signaling in human platelets by compartmentalized cyclic nucleotide actions.
Bilodeau ML; Hamm HE
J Pharmacol Exp Ther; 2007 Aug; 322(2):778-88. PubMed ID: 17525299
[TBL] [Abstract][Full Text] [Related]
19. Contributions of Protease-Activated Receptors PAR1 and PAR4 to Thrombin-Induced GPIIbIIIa Activation in Human Platelets.
Duvernay MT; Temple KJ; Maeng JG; Blobaum AL; Stauffer SR; Lindsley CW; Hamm HE
Mol Pharmacol; 2017 Jan; 91(1):39-47. PubMed ID: 27784794
[TBL] [Abstract][Full Text] [Related]
20. Proteinase-activated receptor 4 (PAR4): activation and inhibition of rat platelet aggregation by PAR4-derived peptides.
Hollenberg MD; Saifeddine M
Can J Physiol Pharmacol; 2001 May; 79(5):439-42. PubMed ID: 11405248
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
